A study of splicing mutations in disorders of sex development by Calais, Flavia Leme de et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://www.nature.com/articles/s41598-017-16296-3
DOI: 10.1038/s41598-017-16296-3
Direitos autorais / Publisher's copyright statement:
©2017 by Springer. All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo
CEP 13083-970 – Campinas SP
Fone: (19) 3521-6493
http://www.repositorio.unicamp.br
1SCiENTiFiC RepoRtS | 7: 16202  | DOI:10.1038/s41598-017-16296-3
www.nature.com/scientificreports
A study of splicing mutations in 
disorders of sex development
Flavia Leme de Calais1,2, Lindsay D. Smith1,3, Michela Raponi1, Andréa Trevas Maciel-Guerra4, 
Gil Guerra-Junior5, Maricilda Palandi de Mello2 & Diana Baralle  1,6
The presence of splicing sequence variants in genes responsible for sex development in humans 
may compromise correct biosynthesis of proteins involved in the normal development of gonads 
and external genitalia. In a cohort of Brazilian patients, we identified mutations in HSD17B3 and 
SRD5A2 which are both required for human sexual differentiation. A number of these mutations 
occurred within regions potentially critical for splicing regulation. Minigenes were used to validate the 
functional effect of mutations in both genes. We evaluated the c.277 + 2 T > G mutation in HSD17B3, 
and the c.544 G > A, c.548-44 T > G and c.278delG mutations in SRD5A2. We demonstrated that these 
mutations altered the splicing pattern of these genes. In a genomic era these results illustrate, and 
remind us, that sequence variants within exon-intron boundaries, which are primarily identified for 
diagnostic purposes and have unknown pathogenicity, need to be assessed with regards to their impact 
not only on protein expression, but also on mRNA splicing.
Discovered in the late 1970s, the splicing process is a crucial step in the biogenesis of eukaryotic mRNA1,2. The 
chemistry of the splicing reaction is mediated by the spliceosome, a ribonucleoprotein complex assembled from 
five subcomplexes called snRNP’s (U1snRNP, U2, U4, U5 and U6)3 which interact with specific sequences at the 
exon/intron boundaries to direct intron excision and exon ligation to produce the mature mRNA4.
The first core splicing signal sequence is the 5′ splice site, which is present at the 5′ end of the intron and 
includes a universally conserved GU dinucleotide (the donor site AG/GURAGU, where R is a purine). The second 
consensus sequence is the 3′ splice site, located at the 3′ end of the intron and defined by three conserved ele-
ments: the branch point (composed of the sequence YNYURAC, where Y is a pyrimidine), polypyrimidine tract, 
and terminal AG at the extreme 3′ end of the intron (the acceptor site YAG/RNNN)5,6.
Auxiliary cis-elements, known as exonic and intronic splicing enhancers (ESEs and ISEs) and silencers (ESSs 
and ISSs), are essential sequences which increase splicing fidelity7. Many ESEs and ISEs contain binding sites for 
members of the SR protein family. SR proteins are often involved in positive regulation of the splicing process and 
promote early spliceosomal complex assembly8. Whereas, the best characterized splicing silencers are recognized 
by heterogeneous nuclear ribonucleoproteins (hnRNPs)9.
Cis-acting mutations can disrupt the use of essential splice sites resulting in loss of gene expression or acti-
vation of alternative splice sites, which force the expression of alternative mRNA isoforms. Importantly, if the 
expression of alternative splicing isoforms occurs at an inappropriate developmental stage this may result in 
disease10. Alterations in the spliceosome machinery and point mutations located at intron-exon boundaries can 
result in severe changes to the splicing processe and thus impact on the appearance of disease11. It has been shown 
that 15–62% of all splicing mutations result in the expression of aberrant mRNA products that directly result in 
disease12–14.
In the present study we have evaluated the effect of mutations within two genes critical for human sexual 
development: HSD17B3 and SRD5A2. These genes are involved in the biosynthesis of steroid hormones, testos-
terone (T) and dihydrotestosterone (DHT) respectively. The HSD17B3 gene produces the 17beta-hydroxysteroid 
dehydrogenase type 3 (17beta-HSD3) enzyme, which catalyzes the synthesis of T from androstenedione (A). The 
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SRD5A2 gene encodes the 5alpha-reductase type 2 enzyme, which converts T to DHT, a more active metabolite15,16. 
Individuals with 17beta-HSD3 or 5alpha-reductase type 2 deficiencies will experience undermasculinization with 
predominantly female external genitalia or may present hypospadias. They are often raised as girls despite the fact 
that they carry a 46,XY karyotype. Deficiencies in either 17beta-HSD3 or 5alpha-reductase type 2 enzymes are 
inherited as autosomal recessive disorders17,18. A limited number of mutations within 5′ and 3′ splice sites have 
been described for these genes19–22.
The aim of this study was to functionally evaluate the effect of sequence variants of unknown significance 
(VUS) within these genes which were predicited to affect splicing: c.277 + 2 T > C in HSD17B3, and c.278delG, 
c.183-44 T > G and c.544 G > A in SRD5A2. For this purpose we developed hybrid minigenes containing either 
wild-type (WT) DNA sequences or DNA from patients carrying the sequence variants. Assessment of the splic-
ing pattern of either WT or mutant minigenes enabled us to determine the effect of the VUS on the splicing 
mechanism.
Results
To functionally validate whether the identified sequence variants disrupted splicing, minigenes containing the 
mutation of interest or the WT sequence were constructed. Each minigene construct was transfected, in triplicate, 
into HEK-293 cells. 48 hours later cells were harvested, RNA purified and the effect on splicing determined by 
semi-quantitative RT-PCR and sequencing.
The c.277 + 2 T > G HSD17B3 mutation located in the 5′ splice site of intron 3 (Fig. 1) was previously 
described in compound heterozygosis with the c.277 + 4 A > T mutation in a 46,XY female patient23. As aberrant 
splicing had already been described for the c.277 + 4 A > T HSD17B3 mutation19, we investigated the affect of 
the c.277 + 2 T > G mutation on splicing. RT-PCR results showed that the c.277 + 2 T > G mutation enhanced 
skipping of exon 3 compared to WT (Fig. 2).
The c.544 G > A SRD5A2 mutation is located in the last nucleotide of exon 3 (5′ splice site) (Fig. 3). The DNA 
used for this assay was obtained from a homozygous 46,XY female patient described elsewhere24. Assessment of 
c.544 G > A minigene splicing showed that this mutation promoted skipping of exon 3 (Fig. 4), which may result 
in an alteration of 5α-reductase type 2 protein expression and lead to the disease phenotype.
The c.278delG SRD5A2 mutation is located within the 5′ splice site of exon 1 (Fig. 3). This mutation was 
identified in compound heterozygosis with p.Gly196Ser21 in a 46,XY patient with ambiguous genitalia24. Analysis 
of the amino acid sequence showed that the c.278delG mutation resulted in a frameshift that generates a prema-
ture stop codon at position 121 (p.Val81Leufs*121). Additionally, RT-PCR and sequencing results showed that 
c.278delG promoted the use of a cryptic 5′ splice site at c.243 resulting in a transcript with a 38-nucleotide dele-
tion at the 3′ end of exon 1 (Fig. 5).
We evaluated the SRD5A2 sequence variant c.548-44 T > G, located at the 3′ splice site of intron 3 (Fig. 3). 
This mutation was identified in a heterozygous 46,XY DSD patient that had palpable gonads in the labioscrotal 
folds and male genitalia. RT-PCR results showed that both WT and mutant minigenes produced three tran-
scripts. Sequencing identified that they corresponded to: the WT transcript sequence (369 bp); a transcript with 
deletion of 112 nucleotides at the 3′ splice site of exon 4 (Splice Variant 1 = 257 bp); and a transcript with exon 4 
skipping (Splice Variant 2 = 217 bp). The band intensity of the 3 transcripts differed between the WT and mutant 
c.548-44 T > G minigenes. In the WT minigene Splice Variant 1 was most prevalent (66%), whereas the mutant 
minigene produced both Splice Variant 1 and 2 with similar band intensity (42% and 40%, respectively) (Fig. 6) 
indicating that the c.548-44 T > G alteration results in an imbalance of these 3 transcripts. As it was found in 
simple heterozygosis, it is difficult to estimate if this contributes to the less penetrant phenotype of the patient.
Discussion
Genetic analysis of several genes, including ataxia telangiectasia mutated (ATM), neurofibromin 1 (NF1), von 
Willebrand factor (VWF) and cystic fibrosis transmembrane regulator (CFTR), has shown that many exonic and 
intronic alterations, that are classified as neutral/synonymous or missense, have been subsequently found to affect 
the splicing process25,26.
It is well established that one of the earliest events in eukaryotic exon recognition by the spliceosome machin-
ery is binding of U1 small nuclear ribonucleoprotein (snRNP) to the 5′ splice site27,28. U1 snRNP binds to the 
5′ exon-intron junction of pre-mRNA through base pairing between the single stranded terminal sequence of 
Figure 1. Schematic diagram showing the location of the c.277 + 4 A > T mutation in the HSD17B3 gene. Boxes 
represent exons, lines represent introns.
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the U1 RNA molecule and the loosely conserved stretch of nucleotides at the exon-intron boundary (CAG/
GURAGU)29. Subsequent to U1 snRNP binding, ordered assembly of the four remaining snRNPs occurs to form 
the spliceosome, which then undergoes extensive conformational and compositional remodeling to become cat-
alytically active5.
The patient bearing the c.277 + 2 T > G mutation in HSD17B3 was compound heterozygous with the 
c.277 + 4 A > T and was referred to us at the age of 14 years due to lack of female secondary sexual features 
and signs of virilization. The patient presented with a 3-cm phallus, perineal urethral opening, and a vaginal 
introitus and absence of uterus indicated by ultrasound. The gonads were not palpable. The patient also had 
Figure 2. RT-PCR results from transfections of wild-type HSD17B3 or c.277 + 2 T > G HSD17B3 minigenes. 
A representative agarose gel (n = 3) showing the results of RT-PCR of wild-type (WT) and mutant (MUT) 
minigene splicing is shown and quantified for the accompanying graph. Schematic diagrams identifying wild-
type splicing (293 bp) and exon 3 skipping (217 bp) are shown. The panel on the right shows electropherograms 
of cDNA splicing isoforms generated from wild-type and mutant minigenes. The histogram shows the relative 
percentage expression of each isoform calculated against total intensity of the bands representing each isoform. 
Student t test analysis shown; *p < 0.01.
Figure 3. Schematic diagram showing the location of c.278delG, c.183-44 T > G and c.544 G > A mutations in 
the SRD5A2 gene. Boxes represent exons, lines represent introns.
www.nature.com/scientificreports/
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hirsutism and pubic hair stage 4 with karyotype 46,XY. Molecular findings and minigene experiments confirmed 
the 17β-hydroxysteroid dehydrogenase type 3 deficiency as the ethiology for 46,XY DSD in this case.
Figure 4. RT-PCR results from transfections of wild-type SRD5A2 or c.544 G > A SRD5A2 minigenes. A 
representative agarose gel (n = 3) showing the results of RT-PCR of wild-type (WT) and mutant (MUT) 
minigene splicing is shown and quantified for the accompanying graph. Schematic diagrams identifying wild-
type splicing (317 bp) and exon 3 skipping (217 bp) are shown. The panel on the right shows electropherograms 
of cDNA splicing isoforms generated from wild-type and mutant minigenes. The histogram shows the relative 
percentage expression of each isoform calculated against total intensity of the bands representing each isoform. 
Student t test analysis shown; *p < 0.01.
Figure 5. RT-PCR results from transfections of wild-type SRD5A2 or c.278delG SRD5A2 minigenes. A 
representative agarose gel (n = 3) showing the results of RT-PCR of wild-type (WT) and mutant (MUT) 
minigene splicing is shown and quantified for the accompanying graph. Schematic diagrams identifying wild-
type splicing (479 bp) and a transcript with the deletion of 38 nucleotides (441 bp) are shown. The panel on the 
right shows electropherograms of cDNA splicing isoforms generated from wild-type and mutant minigenes. 
The histogram shows the relative percentage expression of each isoform calculated against total intensity of the 
bands representing each isoform. Student t test analysis shown; **P ≤ 0.001.
www.nature.com/scientificreports/
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Because c.544 G > A in SRD5A2 is located at the last nucleotide on exon 3, we wanted to identify whether its 
pathogenic effect could be due to aberrant splicing rather than disruption of SRD5A2 enzymatic activity caused 
by the missense mutation, p.Gly183Ser, as previously considered21. The patient, homozygous for the mutation 
c.544 G > A, was referred to us with 22 days of age due to genital ambiguity. The patient’s parents were first cousins 
and there were no other cases of genital ambiguity in the family. On physical examination the patient had a 1-cm 
phallus, perineal urethral opening and a vaginal introitus; there was a slight posterior labioscrotal fusion. Both 
gonads were palpable in the labioscrotal folds. The patient’s karyotype was 46,XY and sex assignment was female. 
The molecular study confirmed 5-alpha reductase type 2 gene deficiency and analysis of minigene splicing iden-
tified that the pathogenicity of this mutation may, at least partly, be the result of aberrant splicing which resulted 
in exon 3 skipping of SRD5A2.
The results so far described here support the conclusion that c.277 + 2 T > G in HSD17B3 and c.544 G > A in 
SRD5A2 potentially disrupt binding of U1snRNP to the 5′ splice site therefore inhibiting splicing initiation29,30. 
These mutations highlight the importance of a conserved 5′ splice site sequence for correct binding of U1 snRNP 
and spliceosome machinery assembly, and show that disruption of this process may result in human disease30,31.
Exonic and intronic variants may also affect splicing either by creation of new splice sites, activation of existing 
cryptic splice sites, or disruption/creation of other splicing regulators such as enhancers and silencers32. This was 
the case for the TP53 c.672 G > A mutation that results in activation of a cryptic 5′ splice site and the expression 
of an alternative splicing isoform producing a frameshift and activating a premature stop codon33. In this study 
we have described the c.278delG SRD5A2 mutation, which sees firstly, the activation of a cryptic 5′ splice site, and 
secondly a frameshift that activates a premature stop codon. The patient was carrying the c.278delG mutation 
in compound heterozygosis with p.Gly196Ser. This patient was referred to us at the age of 5 years due to genital 
ambiguity. At physical examination, the patient had a 3-cm phallus, penoscrotal hypospadia, the right gonad 
was not palpable and the left gonad was palpable in the inguinal channel. The karyotype was 46,XY, therefore 
the patient was diagnosed with idiopathic 46,XY DSD. As the c.278delG minigene produced a short aberrant 
splicing isoform compared to WT, and also activated a premature stop codon, we can conclude that the c.278delG 
mutation may contribute to the observed genital ambiguity and 5alpha-reductase type 2 deficiency in this case.
Although the analysis of intronic sequence variants has been over looked for diagnostic purposes, their 
importance cannot be neglected as they may also affect the splicing process3. This study highlights the relevance 
of splicing analysis to verify the pathogenicity of such variants, especially those that are rare. Intronic splicing 
variants are often located within 50 base pairs of splice sites, but they have also been reported deep within introns 
where they can be more than 100 base pairs away from exon–intron boundaries34. For example, the deletion of 4 
base pairs (GTAA) in intron 20 of ATM, ~3 kb from exon 20 and 0.8 kb from exon 21, leads to the activation of a 
pseudo exon, producing an aberrant mRNA and consequently the disease phenotype35. In addition, the NF1 deep 
Figure 6. RT-PCR results from transfection of wild-type SRD5A2 or c.548-44 T > G SRD5A2 minigenes. 
A representative agarose gel (n = 3) showing the results of RT-PCR of wild-type (WT) and mutant (MUT) 
minigene splicing is shown and quantified for the accompanying graph. Schematic diagrams identifying the 
wild-type transcript (369 bp), a transcript with deletion of 112 nucleotides (257 bp), and a third transcript with 
exon 4 skipping are shown (217 bp). The panel on the right shows electropherograms of cDNA splicing isoforms 
generated from wild-type and mutant minigenes. The histogram shows the relative percentage expression of 
each isoform calculated against total intensity of the bands representing each isoform. Student t test analysis 
shown; *p < 0.01.
www.nature.com/scientificreports/
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intronic single nucleotide change, c.31–279 A > G, which results in creation of a 3′ splice site, illustrate how such 
variants can activate cryptic 5′ splice sites and partial inclusion of a pseudoexon36. Mutations that inactivate or 
activate alternatively used splice sites could force the expression of one alternative splicing pattern over another, 
thus potentially favoring the expression of protein isoforms which could be incompatible with a certain cell type, 
developmental stage, or result in disease37. This was probably the case for the variant c.548–44 T > G, a very rare 
variant (0.2%, unpublished data) described here in a heterozygous 46,XY DSD patient. The patient was referred 
to us at the age of 4 years due to unilateral cryptorchidism and the older brother also had cryptorchidism. The 
patient presented a 4-cm phallus and typical male genitalia; the left gonad was palpable in the inguinal channel 
and the right gonad in the labioscrotal fold. His karyotype was 46,XY. Because of the heterozygosis of this muta-
tion screening of other genes that could be potentially involved in the phenotype of the patient was performed. 
Sequencing of exons and intron/exon boundaries of AR, HSD17B3, and NR5A1 genes did not identify any signif-
icant sequence variants. Therefore we concluded that the c.548-44 T > G mutation may cause the phenotype by 
mediating an imbalance of isoform expression which leads directly to genital ambiguity.
Research is still unraveling many of the basic mechanisms that underlie the pre-mRNA splicing process. 
Clinical cases that identify mutations affecting splicing are useful for highlighting these mechanisms and how 
they can be disrupted in disease, which is important in diagnostic and therapeutic research. Clinically important 
mutations that affect the splicing process have been difficult to characterize using current diagnostic algorithms 
and techniques, particularly in SRD5A2, HSD17B3 and other genes associated with disorders of sex development. 
Our findings have not only contributed to the phenotypic understanding of these patients but have also high-
lighted that analysis of sequence variants, not classically affecting protein function, should be assessed for their 
effect on splicing function to confirm pathogenicity. If RNA is readily available this analysis can be undertaken by 
RT-PCR, but if not available, as in this study, further confirmation can be achieved by minigene splicing assays. 
Analysis of splicing mutations is important for both clinical diagnosis and management, and for developing 
our understanding of underlying pathogenic splicing mechanisms, which will in-turn expand our knowledge of 
endocrine regulation in sexual differentiation.
Materials and Methods
Minigene construction. Patient or control DNA was used for PCR amplification with oligonucleotides car-
rying a non-complementary tail for specific restriction enzyme digestion. PCR products were sub-cloned into the 
pGEM vector (Promega) following manufacturer’s instructions. Sub-cloned PCR fragments and a pCDNA3(+) 
vector (Invitrogen) containing exons and introns 1–3 of the human alpha globin (HBA1) gene were digested 
using BamHI, EcoRI and KpnI before ligation38. The sequence of all minigenes were checked by sequencing.
Cell Culture. Human Embryonic Kidney cell lines (HEK-293), were grown in DMEM medium supplemented 
with 1% streptomycin and 10% fetal bovine serum, and incubated in 5% CO2 at 37 °C.
Transfection. Minigenes were transfected into HEK-293 cell lines using FuGENE HD (Roche). A mix of 
100 μl of DMEM serum-free medium containing 1 ug of vector DNA and 3 μl of FuGENE reagent was incubated 
for 15 minutes at room temperature before being added to 6 cm-well cell cultures (60% confluent) in the presence 
of 10% fetal bovine serum.
RNA Extraction and RT-PCR. RNA was extracted from cells 48 hours after transfection using an RNeasy® 
Plus Mini Kit (Qiagen), following manufacturer’s instructions. cDNA sysntheis was performed on 1 μg total RNA 
using random primers and Promgea M-MLV Reverse Transcriptase (Promega). PCR was performed on resulting 
cDNA using specific primers to the α-globin gene: forward primer 5′ GGACCCGGTCAACTTCAA 3′; reverse 
primer 5′ AGCTCTAGCATTTAGGTGACACTAT 3′, with the exception of the c.278delG mutation (SRD5A2 
gene) where the forward primer used was: 5′TAATACGACTCACTATAGGG 3′. PCR products were analyzed by 
electrophoresis on 1.5% agarose gels and band intensity quantified using IMAGEJ. To account for differences in 
product length, band intensities of each splicing isoform were normalized to the length of the wild-type splice for 
each minigene. The relative band intensity of each isoform was then calculated as a percentage of the total expres-
sion of all isoforms following normalization. Statistical analysis (student’s t test) was performed using GraphPad 
Prism software.
cDNA Sequencing. Individual PCR fragments were purified using the GeneJET Gel Extraction Kit (Thermo 
Scientific). Confirmatory sequencing of RT-PCR products was performed with primers used in the PCR reac-
tion. Chromas Lite 2.0 (Technelysium Pty) and CLC Sequence Viewer v.6.8.1 (Qiagen) were used to align and 
analyse cDNA and amino acid sequences against reference sequences available through the Ensembl database 
(SRD5A2:ENSG00000277893; HSD17B3: ENSG0000013094839.
In silico analysis. Splicing regulatory sequences in SRD5A2 and HSD17B3 genes were predicted using the 
computational tools SpliceAid, and Human Splicing Finder version 2.4.140,41.
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